TY - JOUR
T1 - Correction to
T2 - A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma (International Journal of Hematology, (2019), 109, 1, (107-114), 10.1007/s12185-018-2543-y)
AU - on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)
AU - Fuchida, Shin ichi
AU - Sunami, Kazutaka
AU - Matsumoto, Morio
AU - Okumura, Hirokazu
AU - Murayama, Tohru
AU - Miyamoto, Toshihiro
AU - Otsuka, Eichi
AU - Fujishima, Naohito
AU - Izumi, Tohru
AU - Tamaki, Shigehisa
AU - Hiramatsu, Yasushi
AU - Kuroda, Yoshiaki
AU - Shimazaki, Chihiro
AU - Akashi, Koichi
AU - Harada, Mine
N1 - Funding Information:
Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shin-yaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Jans-sen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.
Publisher Copyright:
© 2018, The Japanese Society of Hematology.
PY - 2019/1/22
Y1 - 2019/1/22
N2 - In the original publication of this article, “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading. Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.
AB - In the original publication of this article, “Conflict of interest” was published incorrectly. The corrected “Conflict of interest” is given below for your reading. Conflict of interest Dr. Sunami reports grants from GlaxoSmithKline, Novartis, Janssen, Sanofi, MSD, Alexion Pharma, Daiichi-Sankyo, and Abbvie, and grants and personal fees from Ono pharmaceutical, Takeda pharmaceutical, Celgene, and Bristol-Myers Squibb. Dr. Matsumoto reports personal fees from Celgene, Janssen, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda Pharmaceutical. Dr. Okumura reports personal fees from Celgene. Dr. Murayama reports personal fees from Bristol-Myers Squibb, Celgene, Eisai, Janssen, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Sanofi, Siemens Healthcare Diagnostics, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Mundipharma, Beckman Coulter, and Chugai Pharmaceutical. Dr. Miyamoto reports personal fees from Celgene. Dr. Shimazaki reports personal fees from Ono Pharmaceutical, Celgene, and Fujimoto Pharmaceutical. Dr. Akashi reports personal fees from Celgene and Janssen, grants from Nippon Kayaku, and grants and personal fees from Kyowa Hakko Kirin, Takeda Pharmaceutical, Shionogi, and Mochida Pharmaceutical. Dr. Harada reports personal fees from Celgene.
UR - http://www.scopus.com/inward/record.url?scp=85056133834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056133834&partnerID=8YFLogxK
U2 - 10.1007/s12185-018-2557-5
DO - 10.1007/s12185-018-2557-5
M3 - Comment/debate
C2 - 30406327
AN - SCOPUS:85056133834
SN - 0925-5710
VL - 109
SP - 131
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 1
ER -